Loading organizations...
Tome Biosciences is a biotechnology company focused on programmable genomic integration (PGI), developing advanced gene editing technologies. Its platform precisely inserts large genetic sequences into the genome at specific locations using novel CRISPR-based systems. This approach facilitates permanent therapeutic gene addition, overcoming traditional gene therapy limitations by integrating material without unwanted disruptions. This versatile technology offers a platform for therapeutic applications.
Founded in 2021, Tome Biosciences emerged from the pioneering research of co-founders Jonathan Gootenberg and Omar Abudayyeh. Their collaborative work at the Massachusetts Institute of Technology led to the discovery of PGI's underlying technology. The core insight was to move beyond simply cutting DNA, achieving a controlled, efficient method for large gene insertion, addressing intractable genetic conditions.
Tome Biosciences' technology serves patients with serious genetic diseases requiring definitive gene correction. By enabling precise, stable integration of therapeutic genes, the company aims to develop curative therapies for many conditions where gene replacement or modification is critical. Their long-term vision is to usher in a new era of genomic medicines, providing durable and transformative treatments through their programmable gene insertion platform.
Tome Biosciences has raised $210.0M across 1 funding round.
Tome Biosciences has raised $210.0M in total across 1 funding round.
Tome Biosciences has raised $210.0M in total across 1 funding round.
Tome Biosciences's investors include Andreessen Horowitz, ARCH Venture Partners, Bessemer Venture Partners, Daniel Lynch, GV, Polaris Partners, Timothy A. Springer, Alexandria Venture Investments, Jorge Conde, Bio + Health, Bruker, Fujifilm.
Tome Biosciences was a biotechnology company developing Programmable Genomic Integration (PGI), a gene-editing platform to insert large DNA sequences precisely into the genome without double-strand breaks, targeting diseases like liver disorders, Duchenne muscular dystrophy, and autoimmune conditions.[1][2][3] It served patients with complex genetic diseases and cell therapy developers by enabling safer, more effective genomic reprogramming, likened to a "word processor" for DNA.[2][3] Launched in December 2023 with $213 million in Series A and B funding from investors like a16z Bio + Health, ARCH, and GV, Tome showed early promise but collapsed by November 2024 due to rapid cash burn, layoffs, and shutdown amid high costs and strategic errors.[1][3]
Tome Biosciences emerged from stealth in December 2023, founded by Jonathan Weissman and Omar Abudayyeh, scientists whose MIT-licensed research underpinned PGI, demonstrated in a 2022 Nature paper showing insertion of up to 36,000-base sequences across cell types without DNA breaks.[2][3] CEO Rahul Kakkar, a physician and serial entrepreneur who sold his prior company for nearly $2 billion, led the team alongside CSO John Finn (ex-Intellia CRISPR clinician), CTO Matt Barrows (Moderna vaccine scale-up), and operations experts Ed Freedman and Diane Wong.[3] The idea stemmed from advancing beyond CRISPR's limitations, with initial traction from $213 million funding to pursue in vivo liver disease therapies and ex vivo autoimmune cell therapies.[1][2][3] Pivotal early moves included acquiring Replace Therapeutics for $65 million (up to $185 million total) to bolster CRISPR tech, but this strained resources.[1]
Tome rode the genomic medicine 3.0 wave post-CRISPR (Nobel/FDA-approved), addressing limitations in inserting large payloads for hard-to-treat diseases amid booming gene therapy demand.[3] Timing aligned with maturing cell therapy ecosystems and investor enthusiasm for "software-like" DNA editing, fueled by successes like Moderna's scale-up and Intellia's clinic entry.[1][3] Market forces favored it: rising autoimmune/chronic disease prevalence, need for non-breakage editing to avoid off-target risks, and VC influx into biotech (evident in its $213M raise).[2][3] However, Tome highlighted ecosystem risks—high burn rates, premature acquisitions, and data costs—exposing biotech's "valley of death" for pre-clinical platforms, influencing investor caution on unvalidated tech buys.[1]
Tome's swift rise and fall underscore biotech pitfalls: over-expansion, costly acquisitions like Replace Therapeutics, and leadership gaps burned $213 million in under a year, ending in full layoffs by November 2024.[1] No revival signs post-shutdown; assets or IP may have been absorbed quietly, but its PGI tech could resurface via acquirers targeting genomic integration.[1] Trends like AI-accelerated drug design and safer editing (e.g., prime editing evolutions) will shape successors, potentially redeeming Tome's vision in a more capital-efficient ecosystem. This cautionary tale reminds investors that even MIT-backed, VC-fueled platforms must prioritize milestones over hype to endure.
Tome Biosciences has raised $210.0M across 1 funding round. Most recently, it raised $210.0M Series A in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2023 | $210M Series A | — | Andreessen Horowitz, ARCH Venture Partners, Bessemer Venture Partners, Daniel Lynch, GV, Polaris Partners, Timothy A. Springer, Alexandria Venture Investments, Jorge Conde, BIO + Health, Bruker, Fujifilm, Longwood Fund, Alan Crane | Announced |
